Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 23/04/20101 min de lecture
Determination of Regulatory Review Period for Purposes of Patent Extension; VIMPAT-NDA 22-254
Traduction automatique locale · Langue originale de la source
Résumé
The Food and Drug Administration (FDA) has determined the regulatory review period for VIMPAT based on new drug application (NDA) 22-254 for VIMPAT injection and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim the human drug product, VIMPAT. The regulatory review period determination for VIMPAT Tablets is publishing in this issue of the Federal Register.
Langue originale de la source: Federal Register — Health and Human ServicesOuvrir le communiqué original →